Evaluation of the analytical performance characteristics of NT-proBNP immunoassay on Dimension® RxL-HM (Dade Behring);Évaluation des performances analytiques du dosage du NT-proBNP sur automate d'immunoanalyse Dimension® RxL-HM (Dade Behring)

Annales de Biologie Clinique

Volumn 63, Issue 4, 2005, Pages 411-416

  Benoit, M O ^a   Dautezac, F ^a   Taccoen, M ^a   Paul, J L ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Analytical performance; Dimension HM; NT proBNP

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; AUTOMATION; BLOOD; CONGESTIVE HEART FAILURE; HUMAN; IMMUNOASSAY; METHODOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

AUTOMATION; BIOLOGICAL MARKERS; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 23644458587     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Remme WJ, Swedberg K. Guidlines for the diagnosis and treatment of chronic heart failure. Task Force Report. Eur Heart J 2001 ; 22 : 1527-60.
2. Levin E, Gardner D, Samson W. Natriuretic peptides. N Engl J Med 1998 ; 339 : 321-8.
3. Hammerer-Lercher A, Neubauer E, Müller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal probrain natriuretic peptide in diagnosis left ventricular dysfunction. Clin Chim Acta 2001 ; 310 : 193-7.
4. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004 ; 110 : 2168-74.
5. Williams S, Ng L, O'Brien R, Taylor S, Wright D, Tan L. Is plasma N-BNP a good indicator of the functional reserve of failing hearts ? The FRESH-BNP study. Eur J Heart Fail 2004 ; 6 : 891-900.
6. De Lemos J, Morrow D, Bentley J, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001 ; 14 : 1014-21.
7. Heeschen C, Hamm C, Mitrovic V, Lantelme N, White H. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation 2004 ; 110 : 3206-12.
8. Vassault A, Azzedine MC, Bailly M, et al. Protocole de validation de Techniques (Document B, stade 3). Ann Biol Clin 1986 ; 44 : 686-745.
9. Vassault A, Baud M, Castagnier M, et al., (Commission"Validation de techniques de la SFBC et groupe de travail SFBC/Corata : Comparaison de techniques"). Recommandations pour la comparaison de techniques (Document F). Ann Biol Clin 1992 ; 50 : 727-30.
10. Vassault A. Procédure de validation d'une technique. Spectra Biologie 1997 ; 16 : 43-50.